Regarding the question of whether the shRNA for P2Y1 silencing targeted by astrocytes in this investigation could be employed in clinical settings, we can insist that no adverse effect was observed in AD mice treated with P2Y1-shRNA-AAV in the brain. Here, P2RY1 is linked to Alzheimer disease.